Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1

Conditions

Pancreatic Neoplasms 2Melanoma 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Astrocytoma 2Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1

Interventions

selpercatinib 3Trastuzumab 2Radiotherapy 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1trametinib 1tovorafenib 1tipifarnib 1sargramostim 1pralsetinib 1mercaptoundecahydrododecaborate 1entrectinib 1dabrafenib 1cobimetinib 1alectinib 1aldesleukin 1Vemurafenib 1Taxes 1Tamoxifen 1Ritonavir 1Paclitaxel 1Nivolumab 1Interleukin-12 Subunit p35 1Interleukin-12 1Indinavir 1Famotidine 1Doxorubicin 1Cisplatin 1Bortezomib 14-boronophenylalanine-fructose 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Cancer, Papillary × tovorafenib × Gastrointestinal × Clear all
NCT04985604 2025-10-02

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Day One Biopharmaceuticals, Inc.

Phase 2 Terminated
23 enrolled 15 charts
CNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckThoracic

Thyroid Cancer, Papillary, Astrocytoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡